A Phase 1/2 Randomized, Observer-Blind Study of the Safety, Reactogenicity, and Immunogenicity of 3 SARS-CoV-2 RNA Vaccine Candidates in Adults Previously Vaccinated and Not Previously Vaccinated Against SARS-CoV-2
Latest Information Update: 01 Aug 2024
At a glance
- Drugs ARCT 021 (Primary) ; ARCT-154 (Primary) ; ARCT-165 (Primary)
- Indications COVID 2019 infections; SARS-CoV-2 acute respiratory disease
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Arcturus Therapeutics
- 30 Jul 2024 Status changed from recruiting to completed.
- 14 Nov 2023 According to an Arcturus Therapeutics media release, data from this trial were presented at the 9th ESWI Influenza Conference in Valencia.
- 19 Sep 2023 According to an Arcturus Therapeutics media release, 36 adults previously immunized with approved COVID-19 mRNA vaccines as a primary series were recruited.